Sir,

A 61-year-old male patient presented with three months history of intermittent high-grade fever, right upper quadrant pain, and dry cough. Two weeks before, he also developed severe pain in the left hip. He was diagnosed to have diabetes mellitus 6 months earlier for which he was not on treatment. His total leukocyte count was 8500/cumm. His random blood sugar was 562 mg/dl and glycated hemoglobin was 16.6%. Computed tomography scan of the abdomen revealed multiple hypodense lesions in the liver suggestive of abscesses \[[Figure 1](#F1){ref-type="fig"}\]. His blood culture grew *Klebsiella pneumoniae* sensitive to amikacin, meropenem, gentamicin, piperacillin-tazobactam, and ciprofloxacin. The bone scan revealed uptake in the left femur suggestive of osteomyelitis. He was treated initially with piperacillin-tazobactam followed by levofloxacin for 6 weeks with which he improved well. String test, the phenotypic test for hypermucoviscous type of *K. pneumoniae*, was positive. The *K. pneumoniae* isolate was characterized for virulence determinants, which included mucoviscosity-associated gene A (*magA*), regulator of mucoid phenotype A (*rmpA*) and *rmpA2* genes.\[[@ref1]\] Polymerase chain reaction was performed for these genes with primers as previously described in literature. The amplified products were sequenced (ABI Prism 3100 Genetic Analyzer - Applied Biosystems) and confirmed. The GenBank sequence accessions numbers obtained for *magA*, *rmpA*, and *rmpA2* are KU761257, KU761255, and KU761256, respectively. Multilocus sequence typing (MLST) was performed with seven genes (*gapA*, *infB*, *mdh*, *pgi*, *phoE*, *rpoB*, and *tonB*) with primers as described by Diancourt *et al*.\[[@ref2]\] The sequence type was determined as ST23 using the MLST database for *K. pneumoniae* at [www.pasteur.fr/mlst/Kpneumoniae.html](http://www.pasteur.fr/mlst/Kpneumoniae.html).

![(a) Computed tomography scan of the liver showing hypoechoic lesion and (b) results of agarose gel electrophoresis of polymerase chain reaction products. Lane 1: DNA Ladder of 100 bp, Lane 2: Mucoviscosity-associated gene A, 1280 bp, Lane 3: Regulator of mucoid phenotype A, 535 bp, Lane4: Regulator of mucoid phenotype A2, 458 bp](JGID-10-30-g001){#F1}

*K. pneumoniae* is frequently associated with infections in patients with impaired host defenses like diabetes mellitus. A distinctive, invasive community-acquired *K. pneumoniae* syndrome with systemic abscess formation, and high fatality has been increasingly reported in the recent decades. Majority of these patients present with a clinical syndrome of a pyogenic liver abscess, with fever, leukocytosis, and upper quadrant abdominal pain. Most of the reports are from the South East Asian countries and the mortality ranges between 11% and 31%.\[[@ref3]\] The high invasiveness of these isolates is related to the enhanced production of extracellular polysaccharides resulting in extreme "stickiness" noticed in agar plate growths. This is related to two genes: the *magA* and the *rmpA* and its variant *rmpA2*.\[[@ref1]\]

Although string test is a sensitive semiquantitative phenotypic test, which can be employed in all laboratories to screen for hypervirulent strains, it lacks specificity.\[[@ref4]\] The *magA* gene is reported to be associated with string test and also with the capsular type K1 in *K. pneumoniae*. The products of *rmpA* and *rmpA2* bind to the regulatory regions of capsular genes and thereby upregulate capsule synthesis.

Hypervirulent *K. pneumoniae* strains are often susceptible to most of the antibiotics including ciprofloxacin, third and fourth generation cephalosporins, and carbapenems. A recent report of carbapenem resistance in hypervirulent *K. pneumoniae* isolates from China is particularly concerning in the Indian setting.\[[@ref5]\] In summary, we report, to our knowledge, the first patient with a hypervirulent *K. pneumoniae* syndrome from India. Increased awareness about this condition would help in earlier diagnosis and appropriate treatment.
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